Professional Development
Putting the Canadian Cardiovascular Society 2022 Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults into Action.
Learning Objectives
Participants will:
- Be updated on the rapidly evolving evidence base supporting use of SGLT2i and GLP-1 RA for cardiorenal risk reduction (Leader, Collaborator, Professional, Expert, Communicator, Scholar)
- Be able to identify opportunities for use of SGLT2i and GLP-1 RA in patients with heart failure or chronic kidney disease with or without type 2 diabetes (Leader, Collaborator, Professional, Expert, Communicator, Scholar)
- Be confident in implementing these new classes through understanding safe strategies for implementation and avoidance of side effects (Leader, Collaborator, Professional, Expert, Communicator, Scholar)
Panelists: Dr. John Mancini (moderator), Dr. Eileen O’Meara, Dr. Alice Cheng, Dr. David Cherney and Dr. David Bewick.